Search

everythinglearnresearchcommunity

for

Search:↓

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.

Finasteride significantly reduces DHT levels in male dogs without affecting testosterone levels, suggesting it could be used to treat benign prostatic hypertrophy in dogs weighing 10 to 50 kilograms.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

Dosing time affects finasteride's effectiveness and safety in rats.

The normal human prostate does not significantly affect blood DHT levels.

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

CAG repeat polymorphism and prostate zone volume are not reliable markers of long-term androgen sensitivity.

5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

Finasteride reduces certain hormone levels to treat prostate issues.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

Germacrene analogs, especially 8-Hydroxy germacrene B, are more effective than germacrone at blocking a hormone-related enzyme and could help treat hair loss.

The root extract of Untica mairei Levl may help treat benign prostatic hyperplasia.

Researchers developed a model to predict how well certain compounds can block an enzyme related to hair loss and prostate issues, suggesting a 50 mg dose of finasteride might be effective based on lab and body data.

The method effectively measures drug impact on DHT levels in prostate treatments.

Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.

Finasteride reduces melanin production in skin cells.

New compounds may soon be tested to treat excessive hair growth in women.

Certain adrenal hormones can strongly stimulate oil gland growth in hamster skin, similar to male hormones.

Higher DHT in male baldness may protect against prostate cancer.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.

Corn silk extract helps reduce prostate enlargement symptoms.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Caesalpinia bonduc seed extracts may help treat enlarged prostate in rats.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

Pueraria mirifica extract may help treat benign prostatic hyperplasia.